Australia markets closed

VRTX Jan 2024 410.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.6000+0.1000 (+6.67%)
At close: 02:12PM EST
Full screen
Previous close1.5000
Expiry date2024-01-19
Day's range1.6000 - 1.6000
Contract rangeN/A
Open interest331
  • Motley Fool

    5 Top Stocks to Buy Before 2024

    One area to focus on is companies that generally offer steady earnings growth over time. CRISPR Therapeutics (NASDAQ: CRSP) just reached a huge milestone, and another may be just ahead. The company recently won the world's first authorization for a CRISPR-based gene-editing treatment when the U.K. gave the nod to exa-cel (to be commercialized as Casgevy).

  • Motley Fool

    Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

    Biotech companies CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) are often mentioned in the same sentence. Vertex is a much larger company with proven innovative abilities, and it has generated strong and consistent revenue, earnings, and stock-market performance in the past decade. CRISPR is a much younger company with a much shorter track record, but could it one day become as successful as its larger partner?

  • Zacks

    Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up

    Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.